Autres langues Ocular Therapeutix, Inc.

Actions

OCUL

US67576A1007

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/05/2024			Varia. 5j.	Varia. 1 janv.
5,795 ^USD	-0,09 %		-6,08 %	+29,93 %

16/05	Transcript : Ocular Therapeutix, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
07/05	Ocular Therapeutix, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	15/05
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside	09/05
Ocular Therapeutix: Q1 Earnings Snapshot	07/05
Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	07/05
Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Ocular Therapeutix™ Reports First Quarter 2024 Results	07/05
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	07/05
Ocular Therapeutix to Present at Two Ophthalmology Meetings, May 4-9, 2024	06/05
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences	06/05
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024	03/05
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024	01/05
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy	19/04
Health Care Flat on Rotation From Rate-Sensitive Sectors -- Health Care Roundup	18/04
Ocular Therapeutix : Amendment No. 3 to 2019 Inducement Stock Incentive Plan - Form 8-K	18/04
Ocular Therapeutix Reports Positive Topline Data in Diabetic Retinopathy Trial; Shares Fall	18/04
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy	18/04
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	18/04
Ocular Therapeutix Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO	16/04
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders	16/04
Ocular Therapeutix CEO Antony Mattessich Steps Down; Pravin Dugel Named Successor	15/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Ocular Therapeutix, Inc.

Actions

OCUL

US67576A1007

Autres langues

Filtres